PC-SOD
- Generic Name
- PC-SOD
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Conditions
- Gynecologic CancerOvarian CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 33
- Registration Number
- NCT06342986
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT03995732
- Locations
- 🇨🇳
Wuhan Asia Heart Hospital, Wuhan, Hubei, China
🇨🇳Zhongshan Hospital, Shanghai, Shanghai, China
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2021-02-10
- Target Recruit Count
- 17
- Registration Number
- NCT02981524
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
- Conditions
- Aplastic Anemia
- Interventions
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Jinan Military General Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT02838992
- Locations
- 🇨🇳
The General Hospital Of Jinan Military Command, Jinan, Shandong, China
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
- Conditions
- Previously Treated Metastatic Adenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2021-04-06
- Target Recruit Count
- 93
- Registration Number
- NCT02243371
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02188368
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
🇺🇸Wellness Oncology and Hematology, West Hills, California, United States
🇺🇸Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2021-03-30
- Target Recruit Count
- 18
- Registration Number
- NCT01966289
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
- Conditions
- LeukemiaHematologic DiseasesLymphoma, Non-HodgkinAcute GVHD
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 11
- Registration Number
- NCT00350181
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.